Probucol improves endothelial-dependent relaxation and decreases vascular superoxide production in cholesterol-fed rabbits

The American Journal of the Medical Sciences
N InoueK Nishida

Abstract

Recent data indicate that hypercholesterolemia increases endothelial superoxide anion (.O2-) production, and that this diminishes the bioactivity of nitric oxide produced in the endothelium. Probucol, a drug commonly employed for treatment of hypercholesterolemia, has antioxidant properties and inhibits oxidation of low density lipoproteins in vitro. We tested the hypothesis that probucol would decrease vascular .O2- production and improve endothelium-dependent relaxations in cholesterol-fed rabbits. Rabbits were divided into four groups: 1) a control group fed a standard diet; 2) a probucol group fed a standard diet containing 0.3% probucol; 3) a hypercholesterolemic group fed a diet containing 0.5% cholesterol; 4) a hypercholesterolemia-probucol group fed a diet containing 0.5% cholesterol and 0.3% probucol. The cholesterol-rich diet markedly increased plasma total cholesterol level and lipid peroxidation in the plasma, as reflected by thiobarbituric acid-reactive substances (TBARS). This concentration of probucol did not lower plasma cholesterol, but markedly reduced TBARS in the plasma of cholesterol-fed rabbits. Aortic segments from cholesterol-fed rabbits produced 1.8-fold more .O2- (assessed by lucigenin-enhanced chemilu...Continue Reading

References

Feb 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·J S BeckmanB A Freeman
Jul 5, 1990·The New England Journal of Medicine·J A PanzaS E Epstein
Mar 4, 1988·Biochimica Et Biophysica Acta·U P Steinbrecher
Aug 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·T KitaC Kawai
Dec 2, 1986·European Journal of Pharmacology·Y OyamaM Kanno
May 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·S ParthasarathyD Steinberg
Feb 1, 1986·The Journal of Clinical Investigation·S ParthasarathyD Steinberg
Sep 1, 1985·Canadian Journal of Physiology and Pharmacology·R L JayakodyC T Kappagoda
Nov 6, 1974·Biochemical and Biophysical Research Communications·S G SligarI C Gunsalus
Dec 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·J F KeaneyJ A Vita
Jun 1, 1993·The Journal of Clinical Investigation·Y OharaD G Harrison

❮ Previous
Next ❯

Citations

Jun 15, 2012·Archivum Immunologiae Et Therapiae Experimentalis·Paulina KleniewskaAnna Gorąca
Dec 21, 2000·Current Atherosclerosis Reports·K D Pfuetze, C A Dujovne
Dec 21, 2000·Current Atherosclerosis Reports·M MaytinJ Loscalzo
Aug 12, 1999·European Journal of Pharmacology·H BultK E Matthys
Dec 1, 2001·Endocrinology and Metabolism Clinics of North America·A A Taylor
Nov 1, 2001·Trends in Cardiovascular Medicine·J L Witztum, D Steinberg
Jan 12, 2002·British Journal of Pharmacology·Victor E EsenabhaluWolfgang F Graier
Feb 24, 2001·Antioxidants & Redox Signaling·D T PriceJ F Keaney
Jul 11, 2013·Oxidative Medicine and Cellular Longevity·Sunil JoshiSaeed R Khan
Sep 23, 2008·Pharmacology & Therapeutics·Stavros SelemidisGrant R Drummond
Jan 12, 2007·Basic & Clinical Pharmacology & Toxicology·Knut S PetterssonKen M Kengatharan
Feb 2, 2006·Clinica Chimica Acta; International Journal of Clinical Chemistry·Katsuyuki NakajimaAkira Tanaka
Feb 5, 2002·Expert Opinion on Pharmacotherapy·S Maxwell, L Greig
Aug 2, 2001·Journal of Atherosclerosis and Thrombosis·Y WatanabeH Yamaguchi

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.